VTGN Vistagen Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1411685 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY230.4%
TTM net income YoY5.3%
TTM EPS YoY29.7%
Revenue 3-yr CAGR43.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,541.9%
Net margin-2,474.5%
FCF margin—
EBITDA margin-2,533.2%
Returns
ROE-144.9%
ROA-113.0%
ROIC (approx.)-1,250.0%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.64x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio3.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.27M | $486,000 | $1.06M | -$227,000 | $1.11M |
| R&D expense | $54.97M | $39.38M | $20.02M | $44.38M | $35.41M |
| SG&A expense | $18.42M | $17.08M | $14.06M | $14.66M | $13.48M |
| Operating income | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M |
| Pretax income | -$69.68M | -$51.41M | -$29.36M | -$59.24M | -$47.76M |
| Income tax | $7,000 | $7,000 | $4,000 | $6,000 | $3,400 |
| Net income | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M |
| EBITDA | -$71.93M | -$55.82M | -$32.89M | -$59.14M | -$47.63M |
| EPS (basic) | -1.83 | -1.67 | -1.52 | -8.51 | -7.38 |
| EPS (diluted) | -1.83 | -1.67 | -1.52 | -8.51 | — |
| Weighted avg. shares (diluted) | 38.07M | 30.88M | 19.35M | 6.96M | — |
| Banking | |||||
| Net interest income | — | — | — | $26,200 | $19,900 |
| Balance sheet | |||||
| Cash & equivalents | $30.79M | $67.13M | $119.17M | $16.64M | $68.14M |
| Short-term investments | $14.61M | $13.35M | $0 | — | — |
| Current assets | $46.94M | $82.08M | $120.67M | $17.51M | $71.00M |
| PP&E, net | $427,000 | $476,000 | $435,000 | $507,000 | $414,300 |
| Total assets | $48.56M | $84.34M | $123.65M | $21.09M | $74.64M |
| Current liabilities | $12.79M | $12.61M | $5.12M | $4.57M | $5.77M |
| Total liabilities | $13.04M | $13.95M | $9.37M | $9.01M | $9.93M |
| Shareholders' equity | $35.52M | $70.39M | $114.29M | $12.08M | $64.72M |
| Cash flow statement | |||||
| Operating cash flow | -$66.44M | -$42.10M | -$25.81M | -$49.72M | -$45.26M |
| Capital expenditure | — | — | $0 | $528,000 | $0 |
| Free cash flow | — | — | -$25.81M | -$50.24M | -$45.26M |
| Investing cash flow | -$877,000 | -$13.15M | -$61,000 | -$740,000 | -$200,400 |
| Financing cash flow | $30.97M | $3.21M | $128.40M | -$1.04M | $10.48M |
| Depreciation & amortization | $199,000 | $150,000 | $127,000 | $130,000 | $153,500 |
| Stock-based compensation | $4.00M | $4.32M | $2.18M | $3.34M | $3.48M |
Free plan shows the latest 5 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.